Esperion Therapeutics Inc. foresees a boost for its oral bempedoic acid from the latest round of US cholesterol treatment guidelines, which promote the use of add-on therapies for further LDL-lowering on top of statins and emphasize cost-effectiveness.
Esperion plans to file bempedoic acid, an oral ATP citrate lyase inhibitor, for approval as a monotherapy and in a...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
